CART peptide levels are altered by a mutation associated with obesity at codon 34 SIR-CART is a regulated neuropeptide that plays a role in many physiological processes including stress, reward and reinforcement and feeding. [1] [2] [3] Recently, del Giudice et al 4 described a missense mutation at codon 34 of proCART that cosegregated with severe early-onset obesity. Our findings show here for the first time that this mutation has a biochemical effect and alters CART peptide levels in cells.
The Leu34Phe mutation in proCART lies immediately adjacent to a cluster of basic amino acids and was therefore hypothesized to alter proCART processing. 4 Accordingly, we characterized proCART processing using human CART cDNA constructs; one expressed a leucine (wild type) while the other expressed a phenylalanine (mutated). These cDNA constructs were transfected into corticotropic AtT20 cells, a cell line that has often been used to study peptide processing. AtT20 cells also express and process CART peptides. 5, 6 Processing of overexpressed human proCART after transfection with the wild-type and mutant cDNAs was analyzed by Western blotting using an antibody (C4) raised against amino acids 66-89 of human proCART. 7 This antibody detects precursor and active forms of CART peptides. Specificity of CART immunoreactivity was demonstrated by pre-absorbing the antibody with an excess of the immunizing peptide prior to the incubation with the membranes.
In the Western blot shown in Figure 1a , the mobility of authentic CART 42-89 is shown in the left lane (arrow head). Also, we have labeled the prominent bands as P1, P2 and P3. P1 and P2 are precursors that may correspond to human CART 1-89 and CART 10-89, and P3 may be CART 42-89. 7, 8 Very little peptide was found in the lane from untransfected AtT20 cells (lane 1) because more extract would be needed to reveal the different CART species. Transfections increased the amount of CART peptides expressed in the cells, as can be seen in Figure 1a (comparing lane 1 with lanes 2 and 3). Interestingly, there was a reduction in P1, P2 and P3 when AtT20 cells were transfected with the mutated cDNA.
To confirm that P1 and P2 were indeed precursor forms of CART peptides, immunoblots were performed using an antibody (C1) that was raised against amino acids 1-26. This antiserum detects human proCART 1-89 and CART 10-89, but does not detect the smaller processed, active CART 42-89 and CART 49-89 peptides. 9 Figure 1b indeed shows that P1 and P2 are precursors. Further, P1 and P2 were decreased in cells transfected with the mutated cDNA ( Figure 1b , lane 2 vs lane 3). We next tested which peptide species were being secreted into the media. AtT20 cells transfected with the wild or the mutated cDNA secreted the overexpressed CART species, P1 and P2. Interestingly, cells transfected with the mutated cDNA CART precursor species were detected using C1 antibody. secreted lower amounts of P1 and P2 than cells transfected with wild-type cDNA (data not shown).
The data presented here clearly show that mutating codon 34 of human proCART alters the levels of CART peptides. While the mutation clearly resulted in altering the levels of the peptides, it did not appear to change the relative levels of the various peptide species. In the case of pro-opiomelanocortin with a mutation in a dibasic processing site, there was a change in relative levels of the various peptides and an appearance of a mutated fusion protein. 10 While a similar change was not observed here, we cannot rule out that such a change might occur in low levels. But perhaps additional mechanisms for the effects of the mutation must also be considered. Recently, Yanik et al 11 suggested that the mutation at codon 34 of proCART may have an impact on CART sorting and trafficking.
In summary, transfection of AtT20 cells with the mutant cDNA resulted in altered levels of CART peptides compared to transfection with the wild-type cDNA. These mutation-induced changes imply that changes in CART peptide levels occur in some tissues in members of an Italian family that carry the mutation and exhibit obesity. In conclusion, our study is the first report that a mutation associated with obesity in fact alters CART peptide levels.
